Editing Microscopic Hematuria (2020 AUA Guidelines) (section)

=== Laboratory ===
* '''Serum creatinine and GFR (NOT required in CUA guidelines)'''
** Goals of renal function assessment in MH patients (2):
**# Identify kidney disease
**#* Abnormal renal function warrants evaluation to include establishing the etiology of renal dysfunction either as it relates to, or independent of, the cause of hematuria
**# Guide the choice of imaging modality, should that be deemed necessary based on patient risk
**** Renal dysfunction increases the risk of contrast or gadolinium radiologic studies and needs to be considered in the selection of these diagnostic procedures.
* '''Urinary markers'''
** '''Urine cytology and urine markers (NMP22, BTA-stat, and UroVysion FISH) are NOT recommended as a part of the routine MH evaluation (CUA Guidelines recommend cytology)'''
** '''Urine cytology may be useful in patients with persistent MH following a negative work up or those with other risk factors for carcinoma in situ'''